Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

98.39 +1.54 (+1.59%)

Streaming Delayed Price Updated: 3:26 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

71 72 Next >

Is BioNTech Stock a Buy Now? ↗

October 25, 2023

Or is it too late to get in on the company after its coronavirus-related success?

Via The Motley Fool

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

October 23, 2023

From BioNTech SE

Via GlobeNewswire

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

October 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END

Via FinancialNewsMedia

8 Analysts Have This to Say About BioNTech ↗

October 17, 2023

Via Benzinga

Price Over Earnings Overview: BioNTech ↗

October 13, 2023

Via Benzinga

A Look Into BioNTech Inc's Price Over Earnings ↗

October 12, 2023

Via Benzinga

BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

October 23, 2023

From BioNTech SE

Via GlobeNewswire

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗

October 21, 2023

The venerable pharmaceutical companies' shares have slumped this year.

Via The Motley Fool

Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research

October 20, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END

Via FinancialNewsMedia

Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry ↗

October 05, 2023

Via Benzinga

Pfizer Reportedly Hikes Paxlovid Price To $1,390 — More Than Double What The Government Paid ↗

October 19, 2023

The transition to the commercial market is planned for 2024 and could bolster sales.

Via Investor's Business Daily

7 Stocks That Are Heading for a Train Wreck ↗

October 19, 2023

There's always a bear market somewhere. Here are seven stocks to sell that investors should definitely unload now.

Via InvestorPlace

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

October 19, 2023

From BioNTech SE

Via GlobeNewswire

Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories ↗

October 16, 2023

Benzinga Bitcoin Spiked On False ETF Approval Rumor

Via Benzinga

Topics ETFs

Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 16, 2023

Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.

Via Benzinga

Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion ↗

October 16, 2023

Pfizer cut about $9 billion from its sales expectations for Covid products this year.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 16, 2023 ↗

October 16, 2023

Via Benzinga

Why ContraFect Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket ↗

October 16, 2023

Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves.

Via Benzinga

Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine ↗

October 16, 2023

Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.

Via Benzinga

Pfizer Cuts Annual Revenue Guidance By $9B Amid COVID-19 Vaccine Sales Slump, BioNTech Warns €900M Write-Offs ↗

October 16, 2023

Friday, Pfizer Inc (NYSE: PFE) slashed its full-year earnings and revenue guidance, citing decreasing demand for its

Via Benzinga

BioNTech, Moderna And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 16, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Cut Your Losses: Sell These 7 Weak Stocks Now ↗

October 16, 2023

You can't let weakness in a company or the market damage your portfolio. Avoid disappointing returns by moving on these stocks to sell.

Via InvestorPlace

Is Novavax Stock a Buy Now? ↗

October 16, 2023

Is this company just a pandemic stock?

Via The Motley Fool

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

October 16, 2023

From BioNTech SE

Via GlobeNewswire

Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs

October 16, 2023

From BioNTech SE

Via GlobeNewswire

Week In Review: Two China Biopharmas Announce Billion Dollar Deals ↗

October 14, 2023

MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...

Via Talk Markets

The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments? ↗

October 11, 2023

Vaccine revenue may have slipped but could still represent billions of dollars for these companies.

Via The Motley Fool

7 Innovator Stocks Primed for Exceptional Growth ↗

October 10, 2023

These featured, inventive companies are not only transforming old sectors but also building bridges toward new ones.

Via InvestorPlace

Privatized Vaccine Distribution Sparks Confusion, Payment Challenges ↗

October 09, 2023

As the rollout of the updated COVID-19 vaccine progresses, some individuals have been surprised by requests for upfront payments ranging from $150 to $200.

Via Benzinga

Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute ↗

October 05, 2023

Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin

Via Benzinga

Topics Intellectual Property Lawsuit

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.